Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study.

Date publication

août 2019

Journal

Arthritis & rheumatology (Hoboken, N.J.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François

Tous les auteurs :
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31379105

Résumé

Immune Checkpoint Inhibitors (ICI) for cancer therapy induce frequent Immune Related Adverse Effects (IRAE). Therefore, most patients with Preexisting Autoimmune Diseases (PAD) have been excluded from clinical trials. This study aims to evaluate the safety and efficacy of ICI in patients with PAD and cancer.

Mots clés

autoimmune disease, cancer, immune checkpoint inhibitors, immune-related adverse events, immunotherapy